Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 3, 2007, Pages 532-537

  Selander, Katri S ^a   Brown, David A ^c   Sequeiros, Guillermo Blanco ^d   Hunter, Mark ^c   Desmond, Renee ^b   Parpala, Teija ^d   Risteli, Juha ^d   Breit, Samuel N ^c   Jukkola Vuorinen, Arja ^d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; MACROPHAGE INHIBITORY CYTOKINE 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CYTOKINES; DISCRIMINANT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 34047253916     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0841     Document Type: Article

References (59)

1. Bootcov MR, Bauskin AR, Valenzuela S, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci U S A 1997;94:11514-9.
2. Paralkar VM, Vail AL, Grasser WA, et al. Cloning and characterization of a novel member of the transforming growth factor-β/bone morphogenetic protein family. J Biol Chem 1998;273:13760-7.
3. Fairlie WD, Zhang HP, Wu WM, et al. The propeptide of the transforming growth factor-β superfamily member, macrophage inhibitory cytokine-1 (MIC-1), is a multifunctional domain that can facilitate protein folding and secretion. J Biol Chem 2001;276:16911-8.
4. Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN. MIC-1 is a novel TGF-β superfamily cytokine associated with macrophage activation. J Leukoc Biol 1999;65:2-5.
5. Bauskin AR, Zhang HP, Fairlie WD, et al. The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-β superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J 2000;19:2212-20.
6. Bauskin AR, Brown DA, Junankar S, et al. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 2005;65:2330-6.
7. Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002;359:2159-63.
8. Tong S, Marjono B, Brown DA, et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet 2004;363: 129-30.
9. Wollmann W, Goodman ML, Bhat-Nakshatri P, et al. The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis 2005;26:900-7.
10. Iczkowski KA, Pantazis CG. Overexpression of NSAID-activated gene product in prostate cancer. Int J Surg Pathol 2003;11:159-66.
11. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-5.
12. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
13. Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642-50.
14. Thomas R, True LD, Lange PH, Vessella RL. Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. Int J Cancer 2001;93:47-52.
15. Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004;96:1248-54.
16. Hsieh CL, Oakley-Girvan I, Balise RR, et al. A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet 2001;69:148-58.
17. Wiklund F, Gillanders EM, Albertus JA, et al. Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate 2003;57:290-7.
18. Hayes VM, Severi G, Southey MC, et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006;15:1223-5.
19. Liu T, Bauskin AR, Zaunders J, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63:5034-40.
20. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 2002;23:967-75.
21. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
22. Thalmann GN, Sikes RA, Wu TT, et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000;44:91-103.
23. Burton DW, Geller J, Yang M, et al. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. Prostate 2005;62:275-81.
24. Fisher JL, Schmitt JF, Howard ML, Mackie PS, Choong PF, Risbridger GP. An in vivo model of prostate carcinoma growth and invasion in bone. Cell Tissue Res 2002;307:337-45.
25. Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001;87:348-51.
26. Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001;19:45-51.
27. Rudnicki M, Jensen LT, Iversen P. Collagen derived serum markers in carcinoma of the prostate. Scand J Urol Nephrol 1995;29:317-21.
28. Zhu L, Leinonen J, Zhang WM, Finne P, Stenman UH. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-α1- antichymotrypsin complex together with free or total PSA. Clin Chem 2003;49:97-103.
29. Brown DA, Bauskin AR, Fairlie WD, et al. Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. Biotechniques 2002;33: 118-20.
30. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
31. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-54.
32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
33. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59: 901-8.
34. Akimoto S, Furuya Y, Akakura K, Ito H. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocr J 1998;45:97-104.
35. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88:2919-26.
36. Green JR. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol 2005;44:282-92.
37. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232-41.
38. Diaz-Martin MA, Traba ML, De La Piedra C, Guerrero R, Mendez-Davila C, De La Pena EG. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest 1999;59:125-32.
39. Nakamura T, Scorilas A, Stephan C, et al. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 2003;88:1101-4.
40. Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;12:89-96.
41. Martinez JM, Sali T, Okazaki R, et al. Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. J Pharmacol Exp Ther 2006;318:899-906.
42. Lee SH, Kim JS, Yamaguchi K, Eling TE, Baek SJ. Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 2005;328:63-9.
43. Wilson LC, Baek SJ, Call A, Eling TE. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 2003;105:747-53.
44. Bottone FG, Baek SJ, Nixon JB, Eling TE. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr 2002;132:773-8.
45. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002;23:425-34.
46. Baek SJ, Kim JS, Jackson FR, Eling TE, McEntee MF, Lee SH. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 2004;25:2425-32.
47. de la Piedra C, Castro-Errecaborde NA, Traba ML, et al. Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 2003;331:45-53.
48. Jukkola A, Bloigu R, Holli K, et al. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Anticancer Res 2001;21:2873-6.
49. Ylisirniö S, Sassi ML, Risteli J, Turpeenniemi-Hujanen T, Jukkola A. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 1999;19:5577-81.
50. Luftner D, Jozereau D, Schildhauer S, et al. PINP as serum marker of metastatic spread to the bone in breast cancer patients. Anticancer Res 2005; 25:1491-9.
51. Tähtelä R, Tholix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 1996;16:2289-93.
52. Karan D, Chen SJ, Johansson SL, et al. Dysregulated expression of MIC-1/ PDF in human prostate tumor cells. Biochem Biophys Res Commun 2003; 305:598-604.
53. Veveris-Lowe TL, Lawrence MG, Collard RL. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005;12:631-43.
54. Ishii K, Otsuka T, Iguchi K, et al. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett 2004;207:79-87.
55. Lee DH, Yang Y, Lee SJ, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003;63:4648-55.
56. Zhang Q, Rubenstein JN, Jang TL, et al. Insensitivity to transforming growth factor-β results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP). Mol Endocrinol 2005;19:2390-9.
57. Schiemann WP, Rotzer D, Pfeifer WM, et al. Transforming growth factor-β (TGF-β)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-β receptor. Cancer Detect Prev 2004;28:57-64.
58. Kim IY, Lee DH, Lee DK, et al. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 2003;9: 6046-51.
59. Käkönen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003;97:834-9.